Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAM2 mRNA-LNP
- Development stage
- Preclinical
- Lead developer
- Wuhan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
STAM2 mRNA-LNP is an mRNA-based therapeutic delivered via lipid nanoparticles (LNPs) that encodes signal transducing adaptor molecule 2 (STAM2). Developed by researchers at Wuhan University, it is designed to target osteoclast precursors to prevent and treat weightlessness-induced bone loss and other mechanical skeletal disorders. STAM2 is a component of the endosomal sorting complex required for transport (ESCRT) pathway. By restoring STAM2 expression, the therapy promotes the degradation of serine/threonine kinase 38 (STK38), a Hippo pathway kinase. This degradation prevents the phosphorylation-dependent cytoplasmic retention of TAZ, restoring its nuclear translocation and maintaining redox homeostasis by reducing reactive oxygen species (ROS) accumulation, which ultimately suppresses excessive osteoclast differentiation and bone resorption.
- Other names
- Stam2 mRNA-LNPStam-2 mRNA-LNPStam 2 mRNA-LNP
02
Targets
STK38 (Serine/threonine-protein kinase 38)
Beyond the preview
Go deeper on STAM2 mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAM2 mRNA-LNP.